Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 362,291 Wave Life Sciences Ltd. (NASDAQ:WVE)

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 362,291 shares of the company's stock, valued at approximately $4,482,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.24% of Wave Life Sciences as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of WVE. KBC Group NV acquired a new stake in shares of Wave Life Sciences in the 4th quarter worth $67,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Wave Life Sciences by 126.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 54,267 shares of the company's stock worth $671,000 after acquiring an additional 30,276 shares during the last quarter. James J. Burns & Company LLC increased its stake in shares of Wave Life Sciences by 11.0% in the 4th quarter. James J. Burns & Company LLC now owns 111,111 shares of the company's stock worth $1,374,000 after acquiring an additional 11,000 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Wave Life Sciences by 16.1% in the 4th quarter. Rhumbline Advisers now owns 124,840 shares of the company's stock worth $1,544,000 after acquiring an additional 17,316 shares during the last quarter. Finally, Principal Financial Group Inc. acquired a new stake in shares of Wave Life Sciences in the 4th quarter worth $3,076,000. 89.73% of the stock is owned by institutional investors and hedge funds.

Wave Life Sciences Trading Up 1.0%

WVE stock traded up $0.07 during trading on Thursday, hitting $6.75. 726,792 shares of the company's stock were exchanged, compared to its average volume of 1,307,325. The business has a 50-day moving average price of $6.45 and a two-hundred day moving average price of $10.09. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -6.08 and a beta of -0.92. Wave Life Sciences Ltd. has a 52-week low of $4.25 and a 52-week high of $16.74.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The business had revenue of $9.18 million for the quarter, compared to analysts' expectations of $11.65 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. During the same quarter in the previous year, the firm earned ($0.24) EPS. On average, equities research analysts anticipate that Wave Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Wave Life Sciences news, CEO Paul Bolno sold 169,025 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the completion of the sale, the chief executive officer now owns 338,351 shares in the company, valued at approximately $3,238,019.07. The trade was a 33.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Christian O. Henry sold 10,500 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $9.77, for a total value of $102,585.00. Following the completion of the sale, the director now owns 16,115 shares of the company's stock, valued at approximately $157,443.55. This represents a 39.45% decrease in their position. The disclosure for this sale can be found here. 29.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

WVE has been the subject of a number of recent analyst reports. Wedbush initiated coverage on Wave Life Sciences in a research report on Tuesday, April 8th. They set an "outperform" rating and a $18.00 price objective for the company. Jefferies Financial Group initiated coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They set a "buy" rating and a $26.00 price objective for the company. Cantor Fitzgerald initiated coverage on Wave Life Sciences in a research report on Tuesday, April 29th. They set an "overweight" rating and a $10.00 price objective for the company. Wall Street Zen downgraded Wave Life Sciences from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Finally, HC Wainwright reissued a "buy" rating and set a $22.00 price objective on shares of Wave Life Sciences in a research report on Wednesday, March 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Wave Life Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $21.17.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.